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Background: Although assessment of cardiovascular safety is mandated by regulatory agencies for the
development of new drugs to treat type 2 diabetes, evaluation of their renal safety has been relatively neglected.
Study Design: Individual patient–level data pooled analysis of 13 phase 2 or 3 randomized, double-blind,
placebo-controlled, clinical trials of the dipeptidyl peptidase 4 inhibitor linagliptin.
Setting & Participants: Participants who participated in any of 13 randomized clinical trials and fulfilled pre-
defined inclusion/exclusion criteria, such as being drug-naive (hemoglobin A1c, 7.0%-11.0% [53-97 mmol/mol])
or being on background glucose-lowering therapy (hemoglobin A1c, 6.5%-10.5% [48-91 mmol/mol]).
Intervention: Of 5,466 consenting individuals with inadequately controlled type 2 diabetes, 3,505 received
linagliptin, 5 mg/d, and 1,961 received placebo.
Outcomes: The primary kidney disease outcome was defined as first occurrence during the study of
6 predefined safety end points: new onset of moderate elevation of albuminuria (urinary albumin-creatinine
ratio [ACR] .30 mg/g with baseline values # 30 mg/g), new onset of severe elevation of albuminuria
(ACR . 300 mg/g with baseline values # 300 mg/g), reduction in kidney function (serum creatinine increase
to $250 mmol/L from a baseline value , 250 mmol/L), halving of estimated glomerular filtration rate (loss of
baseline eGFR. 50%), acute renal failure (ascertained from diagnostic codes), or death from any cause.
Measurements: Albuminuria was assessed using ACR. GFR was estimated using the CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration) equation.
Results: Cumulative exposure (person-years) was 1,751 for linagliptin and 1,055 for placebo. The primary
composite outcome occurred in 448 (12.8%) and 306 (15.6%) participants in the linagliptin and placebo
groups, respectively. Linagliptin treatment significantly reduced the hazard of kidney disease events by 16%
compared with placebo (HR, 0.84; 95% CI, 0.72-0.97; P5 0.02).
Limitations: Retrospective and hypothesis-generating study involving short- to midterm clinical trials.
Conclusions: Linagliptin was not associated with increased kidney disease risk in patients with type 2
diabetes. The potential of this drug to improve kidney disease outcomes warrants further investigation.
Am J Kidney Dis. 66(3):441-449. ª 2015 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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therapy; pooled analysis.The number of new medications available for thetreatment of type 2 diabetes has substantially
increased over the past 2 decades.1 The primary goal
of these agents is to effectively lower elevated blood
glucose concentrations in order to reduce the risk of
long-term complications that result from chronic
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y Dis. 2015;66(3):441-449any new agent to also be proved to be safe. Although
speciﬁc aspects of toxicology, including renal
handling of drugs likely to be administered for years,
are routinely evaluated in the very early stages of drug
development, it is only after sufﬁcient clinical expo-
sure that potential safety concerns might become
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Cooper et almeta-analyses of clinical trials pointed out the po-
tential for increased risks of myocardial infarction
associated with the thiazolidinedione rosiglitazone.4,5
Largely as a result of these types of concerns, regu-
latory requirements issued by the US Food and Drug
Administration (FDA) in 2008 stipulate that new type
2 diabetes drugs should rule out an unacceptable in-
crease in cardiovascular risk in phase 2 and phase 3
clinical trials prior to drug approval.6-8
Microvascular complications, such as retinopathy,
nephropathy, and neuropathy, are widespread in type
2 diabetes and account for signiﬁcant morbidity and
mortality.9 Therefore, current treatment goals in
diabetes include prevention of microvascular com-
plications such as preservation of kidney function.2,3
However, an approach to assess kidney disease end
points for novel diabetes drugs is not generally
applied. More commonly, speciﬁc renal data have
been obtained from secondary analyses of cardio-
vascular outcome trials with several studies identi-
fying effects on glomerular ﬁltration rate (GFR),
although this was not the primary end point of those
trials.10-12 Despite the value of acquiring these
important data, such long-term renal safety evidence
has often not been a priority of the clinical trial pro-
gram, but has only become available several years
after drug approval.
Linagliptin, a novel member of the dipeptidyl
peptidase 4 (DPP-4) inhibitor class, has previously
been shown to signiﬁcantly improve glucose control
without causing weight gain or increasing hypogly-
cemia risk.13-15 In accordance with the guidance by
the FDA, an early cardiovascular meta-analysis was
performed that ruled out an unacceptable increase in
cardiovascular risk for this drug and linagliptin was
consequently approved in the United States in May
2011.16 Unlike other members of the DPP-4 inhibitor
class, linagliptin is not primarily cleared by the kidney
and can be prescribed to patients with type 2 diabetes
at one single dose irrespective of kidney function.15,17
Such pharmacologic qualities support the use of lina-
gliptin in a broad range of patients with type 2 diabetes,
including those with increased prevalence and risk of
renal microvascular complications, as well as in pa-
tients with declining kidney function.18 The objective
of this study was to explore kidney disease end points
in a large set of patients with type 2 diabetes treated
with linagliptin. Comprehensive assessments of safety
events were performed by developing a systematic and
innovative approach based on individual-patient data
from a large clinical trials program.
METHODS
Study Design and Data Source
This pooled kidney disease analysis included all randomized,
double-blind, and placebo-controlled clinical trials of linagliptin of44212-week or longer duration for which database lock of either
predeﬁned interim or ﬁnal analysis was completed before February
13, 2011. Individual-patient data from 2 phase 2 and 11 phase 3
trials were included in the data set only if they received either
linagliptin at a dose of 5 mg once daily or placebo. Studies were
conducted globally over periods of 12 to 76 weeks as monotherapy
or in combination with other glucose-lowering agents in patients
with inadequately controlled type 2 diabetes. Open-label extension
periods of primary double-blind randomized clinical trials were not
considered (Table S1, available as online supplementary material).
Detailed study designs and primary and secondary efﬁcacy and
safety results of the individual studies have been published pre-
viously (Table S1).19
All patients provided written informed consent. Local ethics
committees/institutional review boards reviewed and approved all
study protocols. All studies were conducted in accordance with
Good Clinical Practice guidelines and the principles of the
Declaration of Helsinki.
Setting and Participants
Eligibility criteria for each of the 13 trials were similar. Most
relevant common inclusion criteria were age 18 years or older or
21 years or older, diagnosis of type 2 diabetes, and body mass
index # 40 or #45 kg/m2. At screening, hemoglobin A1c levels
ranged either from 7.0% to 11.0% (53-97 mmol/mol) in treatment-
naive participants or from 6.5% to 10.5% (48-91 mmol/mol) in
participants previously treated with one or more glucose-lowering
therapy. In the majority of trials, previous glucose-lowering ther-
apies, if any, had to be unchanged for at least 8 weeks prior to
informed consent. Most relevant common exclusion criteria at
screening included the following: decreased hepatic function
deﬁned by serum levels of either alanine transaminase, aspartate
transaminase, or alkaline phosphatase more than 3 times the upper
limit of normal; myocardial infarction, stroke, or transient
ischemic attack within the previous 3 or 6 months; any require-
ment for hemodialysis within the previous 3 months; and kidney
transplantation.
Individuals whose blood glucose levels were not adequately
controlled during each of the 13 trials received additional rescue
therapy to ensure overall safety, as appropriate.
The pooled population consisted of all randomly assigned in-
dividuals (n5 5,466) who received at least one dose of study drug
(treated set: linagliptin group, n5 3,505; placebo group, n5 1,961).
Kidney Disease End Points
Based on clinical guidelines or recommendations made by
medical associations and regulatory bodies,2,3,7,20 we deﬁned the
primary composite outcome as ﬁrst occurrence of 6 individual and
clinically relevant kidney disease end points: (1) new onset of
moderate elevation of albuminuria (urinary albumin-creatinine ratio
[ACR] . 30 mg/g at any time during study conduct with baseline
values# 30 mg/g), (2) new onset of severe elevation of albuminuria
(ACR . 300 mg/g at any time during study conduct with baseline
values # 300 mg/g), (3) reduction in kidney function (serum
creatinine increase to $250 mmol/L [$2.8 mg/dL] from a baseline
value , 250 mmol/L as deﬁned by European Medicines Agency;
increase observed at a minimum of 2 consecutive visits during study
conduct with a between-visit time window of at least 4 weeks), (4)
halving of estimated GFR (eGFR; loss of baseline eGFR. 50% as
deﬁned by the FDA, and observed at a minimum of 2 consecutive
visits during study conduct with a between-visit time window of at
least 4weeks), (5) incidence of acute renal failure, and (6) death from
any cause. Although similar end points have previously been
interpreted as efﬁcacy parameters in renal studies,10,11 they were
assessed as safety outcomes in the linagliptin program.
Individual components of the primary composite outcome were
deﬁned as secondary outcomes.Am J Kidney Dis. 2015;66(3):441-449
Kidney Disease End Points and LinagliptinKidney Disease Assessments
Kidney function was determined with the CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration) equation.21 Because
themajority of the linagliptin development programwas conducted in
the era before creatinine assay standardization, 1 of the 2 utilized
central laboratories did not perform standardization to isotope-
dilution mass spectrometry (IDMS) values for the measurement of
serum creatinine. Therefore, serum creatinine values from this labo-
ratorywere standardized for appropriate use in theCKD-EPI equation
(ie, reduction by 5%). Albuminuriawas determined at each study visit
by ACR from a spot urine sample at baseline and during the ran-
domized treatment period. Normoalbuminuria was deﬁned as base-
line ACR# 30mg/g, moderate elevation of albuminuria was deﬁned
as baseline ACR . 30 to 300 mg/g, and severe elevation of albu-
minuriawas deﬁned as baselineACR. 300 mg/g.All assessments of
urine and blood were performed at a central laboratory (Quintiles
Laboratories, Clearstone Central Laboratories [formerly MDS
PharmaServices], andCovanceLaboratories).Acute renal failurewas
deﬁned as ID20000003of the standardizedMedDRAquery (Medical
Dictionary for Regulatory Activities, version 14.0) broad search.
Overall death was based on fatal adverse event outcome.
Overall safety assessments included adverse events, vital signs,
and clinical laboratory variables. Based on relevant safety signals
of recent cardiorenal outcomes trials in patients with type 2 dia-
betes and chronic kidney disease (CKD),11 additional adverse
events of special interest for this pooled kidney disease analysis
included hypotension (identiﬁed by investigator from individual
patient report form evaluation) and hyperkalemia (identiﬁed by
central laboratory serum potassium levels . 5.0 mmol/L).
Statistical Analysis
Statistical analyses were performed using SAS, version 9.2,
software (SAS Institute Inc). Analyses were based on individual-
patient data from the treated set. Descriptive statistics were used
for demographic and baseline characteristics, as well as to determine
primary and secondary outcomes (such as incidence, incidence rates
per 1,000 person-years, and time at risk). Comparability between
treatment groups for demographic and baseline characteristics was
explored by applying stratiﬁed 2-sample t tests and Cochran-
Mantel-Haenszel tests, respectively.
The hazard ratio (HR) for the time to ﬁrst event of interest of the
primary composite outcome was calculated using the Cox pro-
portional hazards model with the primary exposure treatment
group. Adjustments were performed for individual studies. Sub-
group analyses of the primary composite outcome were performed
by age, race, and concomitant antihypertensive treatment (with or
without angiotensin-converting enzyme [ACE] inhibitor and/or
angiotensin receptor blocker [ARB] therapy at baseline). Interac-
tion tests were conducted in order to exclude the heterogeneity of
the treatment effect regarding age, race, antihypertensive treat-
ment, kidney function at baseline, and individual studies. These
interaction analyses were performed using an additional Cox
regression model including the respective factor, as well as the
interaction term of the respective factor with treatment.
Statistical analysis of the secondary outcomes was based on the
individual components of the primary composite outcome.
Cox proportional hazards model analyses were also performed
to calculate HRs of adverse events of special interest (ie, hypo-
tension and hyperkalemia). Renal and safety parameters were
reported using descriptive statistics.
RESULTS
Demographic and Baseline Characteristics
This pooled kidney disease analysis includeda total of
5,466 treated individuals: 3,505 received linagliptin,Am J Kidney Dis. 2015;66(3):441-4495 mg, once daily and 1,961 received placebo. Median
treatment exposure was 171 (range, 1-531) days for
linagliptin and 172 (range, 1-531) days for placebo.
Cumulative exposure was 1,751 person-years for lina-
gliptin and 1,055 person-years for placebo. Overall,
participants in the linagliptin group (8.3%) were less
likely to discontinue treatment compared with those
receiving placebo (12.6%).
Demographic and baseline clinical and biochemical
characteristics (Table 1) and background glucose-
lowering and cardiovascular therapies (Table 2) were
well balanced between the 2 treatment groups.
Kidney Disease End Points
Primary Composite Outcome
The primary composite outcome occurred in 448
(12.8%) individuals in the linagliptin group and 306
(15.6%) individuals in the placebo group (Table 3).
Linagliptin treatment signiﬁcantly reduced the hazard
of the ﬁrst occurrence during the study of the primary
composite outcome by 16% as compared with pla-
cebo (HR, 0.84; 95% conﬁdence interval [CI],
0.72-0.97; P 5 0.02; Fig 1). Sensitivity analyses
ruled out a signiﬁcant study by treatment interaction
(P for heterogeneity 5 0.6).
Kidney function at baseline was identiﬁed as a
potential confounder for the primary composite out-
come. Sensitivity analysis showed that adjustment for
kidney function at baseline did not inﬂuence the as-
sociation between reduced renal risk and linagliptin
treatment (HR, 0.83; 95% CI, 0.72-0.97; P5 0.02).
Moreover, the observed risk reduction for kidney
disease end points with linagliptin was consistent
across examined subgroups, including those deﬁned by
race and concomitant use of renin-angiotensin system
(RAS) inhibitors, with borderline evidence of hetero-
geneity in the age subgroup (Table 3; Fig 1B).
Secondary Outcomes
Secondary analyses of the individual components
of the primary composite outcome showed that the
majority of kidney disease end points occurred more
frequently in the placebo group (Table 3). The
overall most frequent event reported was new onset
of moderate elevation of albuminuria, with an inci-
dence rate of 9.3% and 10.9% in the linagliptin and
placebo groups, respectively. Linagliptin treatment
signiﬁcantly reduced the hazard of new onset of
moderate elevation of albuminuria by 18% (HR,
0.82; 95% CI, 0.69-0.98; P 5 0.03; Fig 2). The
second most reported event was new onset of severe
elevation of albuminuria, occurring in 2.4% and
3.2% in the linagliptin and placebo groups, respec-
tively (HR, 0.86; 95% CI, 0.61-1.20; P 5 0.4; Fig 2).
Rare kidney disease end points such as reduction in
kidney function, halving of eGFR, or acute renal443
Table 1. Demographic and Baseline Characteristics
Linagliptin
(n 5 3,505)
Placebo
(n 5 1,961) P a
Age (y) 58.8 6 10.5 59.1 6 10.5 0.7b
,65 y 2,425 (69.2) 1,320 (67.3) 0.7
Male sex 1,844 (52.6) 1,060 (54.1) 0.5
Race 0.5
White 2,250 (64.2) 1,330 (67.8)
Asian 1,179 (33.6) 564 (28.8)
Black 76 (2.2) 67 (3.4)
Body weight (kg) 79.9 6 17.8 82.1 6 17.5 0.1b
Body mass index (kg/m2) 29.26 5.1 29.8 6 5.1 0.2b
eGFR 0.5
$90 mL/min/1.73 m2 1,820 (51.9) 982 (50.1)
60-,90 mL/min/1.73 m2 1,355 (38.7) 748 (38.1)
30-,60 mL/min/1.73 m2 255 (7.3) 167 (8.5)
,30 mL/min/1.73 m2 75 (2.1) 64 (3.3)
Urinary ACR 0.6
#30 mg/g 2,307 (65.8) 1,274 (65.0)
.30-300 mg/g 813 (23.2) 447 (22.8)
.300 mg/g 192 (5.5) 132 (6.7)
Missing 193 (5.5) 108 (5.5)
Time since T2DM diagnosis 0.5
#1 y 422 (12.0) 201 (10.2)
.1-5 y 975 (27.8) 503 (25.7)
.5 y 2,108 (60.1) 1,256 (64.0)
Missing 0 (0.0) 1 (0.1)
HbA1c
c (%) 8.2 (0.9) 8.2 (0.9) 0.2b
HbA1c
c (mmol/mol) 66.06 9.8 66.0 6 9.8
FPGd (mg/dL) 165.86 45.5 165.26 45.9 0.3b
Systolic BPe 131.46 15.8 132.26 15.5 0.7b
Normotensive: ,140
mm Hg
2,438 (69.6) 1,348 (68.7) 0.3
Grade 1: 140-159 mm Hg 880 (25.1) 501 (25.5)
Grade 2: 160-179 mm Hg 160 (4.6) 98 (5.0)
Grade 3: $180 mm Hg 27 (0.8) 14 (0.7)
Diastolic BPe 78.36 9.1 78.3 6 9.3 0.7b
Normotensive: ,90 mm Hg 3,060 (87.3) 1,712 (87.3) 0.7
Grade 1: 90-99 mm Hg 383 (10.9) 215 (11.0)
Grade 2: 100-109 mm Hg 56 (1.6) 26 (1.3)
Grade 3: $110 mm Hg 6 (0.2) 8 (0.4)
Medical history of
hypertension
2,231 (63.7) 1,265 (64.5) 0.7
Medical history of CAD 447 (12.8) 295 (15.0) 0.6
Note: Values for categorical variables are given as number
(percentage); for continuous variables, as mean 6 standard
deviation.
Abbreviations: ACR, albumin-creatinine ratio; BP, blood
pressure; CAD, coronary artery disease; eGFR, estimated
glomerular filtration rate; FPG, fasting plasma glucose; HbA1c,
hemoglobin A1c; T2DM, type 2 diabetes mellitus.
aP for difference between groups calculated by the Cochran-
Mantel-Haenszel test, unless otherwise indicated.
bP calculated by the 2-sample t test.
cBaseline HbA1c data were available for 5,459 (linagliptin,
3,503; placebo, 1,956) participants.
dBaseline FPG data were available for 5,379 (linagliptin,
3,448; placebo, 1,931) participants.
eBaseline systolic and diastolic BP data were available for
5,466 (linagliptin, 3,505; placebo, 1,961) participants.
Table 2. Background Medication at Enrollment
Linagliptin
(n 5 3,505)
Placebo
(n 5 1,961) P a
No. of glucose-lowering
background drugs
0.9
0 583 (16.6) 307 (15.7)
1 1,171 (33.4) 655 (33.4)
$2 1,751 (50.0) 999 (50.9)
Glucose-lowering background
therapy
Monotherapy
Metformin 719 (20.5) 334 (17.0) 0.8
Sulfonylurea 278 (7.9) 158 (8.1) 0.4
Insulin 146 (4.2) 152 (7.8) 0.4
Other 28 (0.8) 11 (0.6) 0.4
Combination therapy
Metformin 1 sulfonylurea 1,093 (31.2) 407 (20.8) 0.9
Metformin 1 insulin 489 (14.0) 483 (24.6) 0.8
Other 169 (4.8) 109 (5.6) 0.4
Antihypertensive background
therapyb
2,229 (63.6) 1,314 (67.0) 0.9
ACE inhibitors 1,028 (29.3) 622 (31.7) 0.7
ARBs 530 (15.1) 295 (15.0) 0.3
b-Blockers 751 (21.4) 465 (23.7) 0.7
Diuretics 605 (17.3) 392 (20.0) 0.9
Calcium antagonists 595 (17.0) 357 (18.2) 0.7
Fixed-dose combinations 381 (10.9) 230 (11.7) 0.9
Other 1 (0.0) 3 (0.2) 0.2
Lipid-lowering background
therapyb
1,483 (42.3) 929 (47.4) 0.1
Statins 1,293 (36.9) 818 (41.7) 0.1
Fibrates 221 (6.3) 133 (6.8) 0.6
Niacin 33 (0.9) 23 (1.2) 0.5
Other 119 (3.4) 83 (4.2) 0.9
Acetylsalicylic acid 1,231 (35.1) 763 (38.9) 0.5
Note: Values are given as number (percentage).
Abbreviations: ACE, angiotensin-converting enzyme; ARB,
angiotensin receptor blocker.
aP for difference between groups calculated by the Cochran-
Mantel-Haenszel test.
bPatients might have had more than one medication.
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Cooper et alfailure were comparable between the linagliptin and
placebo groups (Table 3).
Five (0.1%) and 4 (0.2%) deaths occurred during
the study periods in the linagliptin and placebo
groups, respectively. None of these was considered
drug related by the investigators.
Safety and Tolerability
Overall, clinical adverse events occurred in 2,151
(61.4%) participants in the linagliptin group and
1,242 (63.3%) in the placebo group. The proportion
of participants having drug-related adverse events was
12.9% in the linagliptin group and 13.4% in the
placebo group. Hypotensive episodes, as reported by
investigators, occurred in 11 (0.3%) participants in the
linagliptin group and 7 (0.4%) in the placebo groupAm J Kidney Dis. 2015;66(3):441-449
Table 3. Incidence, Incidence Rates, and Time at Risk of Primary and Secondary Outcomes
Linagliptin (n 5 3,505) Placebo (n 5 1,961)
Incidence IR Time at Risk Incidence IR Time at Risk
Primary Composite Outcomea
Overall 448 (12.8) 268.4 1,669.4 306 (15.6) 311.7 981.6
Age
,65 y 297 (12.2) 259.4 1,145.0 213 (16.1) 331.0 643.5
$65 y 151 (14.0) 287.9 524.4 93 (14.5) 275.1 338.1
Race
White 280 (12.4) 247.1 1,133.0 207 (15.6) 296.4 698.3
Asian 161 (13.7) 323.6 497.6 90 (16.0) 359.7 250.2
Black 7 (9.2) 180.3 38.8 9 (13.4) 272.2 33.1
Antihypertensive treatment
Without ACEi/ARB 224 (11.3) 247.5 904.9 149 (13.9) 289.4 514.8
With ACEi/ARB 224 (14.7) 293.0 764.4 157 (17.7) 336.3 466.8
Secondary Outcomes
Albuminuria
Moderate elevation 326 (9.3) 191.1 1,705.7 213 (10.9) 210.9 1,009.8
Severe elevation 84 (2.4) 48.0 1,751.4 62 (3.2) 59.0 1,051.7
Reduction in kidney function 4 (0.1) 2.3 1,774.6 11 (0.6) 10.3 1,065.1
Halving of eGFR 2 (0.1) 1.1 1,776.7 2 (0.1) 1.9 1,069.3
Acute renal failure 52 (1.5) 29.5 1,764.9 37 (1.9) 34.9 1,060.5
Death 5 (0.1) 2.8 1,777.3 4 (0.2) 3.7 1,069.9
Note: Incidence values are given as number (percentage). IRs expressed per 1,000 person-years; time at risk, in person-years.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular
filtration rate; IR, incidence rate.
aThe primary outcome is a composite of 6 kidney disease end points, listed under the secondary outcomes.
Kidney Disease End Points and Linagliptin(HR, 1.12; 95% CI, 0.43-2.95; P 5 0.8). Elevated
serum potassium levels were documented in 28 (0.8%)
participants in the linagliptin group and 24 (1.2%) in the
placebo group (HR, 1.02; 95% CI, 0.59-1.77; P5 0.9).
Mean changes in eGFR, ACR, blood pressure, and
body weight from baseline to week 24 in the linagliptin
and placebo groups are presented in Table 4. Table S2
provides additional information on blood pressure
changes during interventions as categorized by the In-
ternational Society of Hypertension recommendations.
No signiﬁcant differenceswere observed for changes in
blood pressure among normo- and hypertensive pa-
tients when treated with either linagliptin or placebo.
DISCUSSION
In this pooled kidney disease analysis, a compre-
hensive assessment of kidney disease end points for a
glucose-lowering drug was performed based on
available data from an early clinical development
program. Such safety evaluations have previously
been requested to improve informed treatment deci-
sion making and to weigh overall risks and beneﬁts of
novel glucose-lowering agents as early as possible in
drug development. A recent example of early drug
safety evaluation was the FDA guidance issued in
2008 requesting that all new oral glucose-lowering
drugs for treating type 2 diabetes have to explore
cardiovascular safety prior to regulatory approval.7Am J Kidney Dis. 2015;66(3):441-449However, similar guidance on renal safety has not
generally been requested, although type 2 diabetes is
associated with considerable renal burden. This is
noteworthy because there is a large body of evidence
that supports the view that macro- and microvascular
changes often occur simultaneously and share common
risk factors and underlyingmechanisms.22 Therefore, it
would be of relevance for newdiabetes drugs to provide
early safety information on renal complications in
addition to assessing cardiovascular safety. This
consideration is further supported because individuals
with diabetes per se are known to be at signiﬁcant
increased risk of developingCKD.As the leading cause
of kidney failure in theUnited States, diabetes accounts
for nearly 45% of new cases.23
To further deﬁne the potential impact of a glucose-
lowering drug on renal risk and outcomes, a novel and
systematic approach was developed to assess kidney
disease end points in patients with type 2 diabetes
treated with the DPP-4 inhibitor linagliptin.24
Although several studies have assessed the safety
and tolerability of DPP-4 inhibitors in patients with
type 2 diabetes and decreased kidney function,15,25-27
clinical trials with primary kidney disease outcomes
are currently not available.28 In order to address this
important gap, linagliptin was chosen as an appro-
priate candidate because it does not require dose
adjustment due to nonrenal clearance and thus can be445
Figure 1. Comparison of risk estimates between the linagliptin and placebo groups using a Cox proportional hazards model for the
primary composite outcome defined as first occurrence of new onset of moderate elevation of albuminuria, new onset of severe eleva-
tion of albuminuria, reduction in kidney function, halving of estimated glomerular filtration rate, acute renal failure, or death from any
cause. Adjustments were performed for individual studies and for treatment groups. Primary analysis in all individuals depicted on top
and in selected subgroups below: analyses by age (,65 and $65 years; P for heterogeneity 5 0.04), race (white, Asian, and black;
P for heterogeneity 5 0.7), and concomitant use of renin-angiotensin system inhibitors (with and without; P for heterogeneity 5 0.9).
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, confidence interval.
Cooper et algiven as a single oral dose in patients with type 2 dia-
betes at any stage of decreased kidney function.17,18
It was fortunate that large data sets from phase 2 and
phase 3 clinical trialswere available16 and, importantly,Figure 2. Comparison of risk estimates between the linagliptin a
secondary outcomes (any first occurrence of the individual compon
CI, confidence interval; eGFR, estimated glomerular filtration rate.
446included individuals at increased risk of kidney disease
end points, such as patients with eGFRs, 30 mL/min/
1.73 m2,15 and elderly patients (aged $ 70 years).13
Overall, our pooled kidney disease analysis includednd placebo groups using a Cox proportional hazards model for
ents of the composite kidney disease outcome). Abbreviations:
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Table 4. Change in Renal and Selected Safety Parameters From Baseline to Week 24
Linagliptin (n 5 3,505) Placebo (n 5 1,961)
Baseline
Week 24: Difference From
Baseline Baseline
Week 24: Difference From
Baseline
eGFR (mL/min/1.73 m2) n5 3,505 87.2 6 0.4 n 5 2,661 20.86 0.2 n 5 1,961 85.6 6 0.5 n5 1,413 20.3 6 0.2
Urinary ACR (mg/g)a n5 1,005 311.76 26.2 n 5 707 217.0 6 21.3 n5 580 366.86 33.1 n5 406 19.6 6 25.8
Blood pressure (mm Hg)
Systolic n5 3,505 131.46 0.3 n 5 2,751 20.36 0.3 n 5 1,961 132.26 0.3 n5 1,463 0.0 6 0.4
Diastolic n5 3,505 78.3 6 0.2 n 5 2,751 20.26 0.2 n 5 1,961 78.3 6 0.2 n5 1,463 20.5 6 0.2
Body weight (kg) n5 3,074 80.4 6 0.3 n 5 2,488 0.26 0.1 n 5 1,667 82.2 6 0.4 n5 1,210 0.0 6 0.1
Note: Numbers of patients indicate participants with measurements. Unless otherwise indicated, values given as mean 6 standard
error.
Abbreviations: ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate.
aIn participants with urinary ACRs $ 30 mg/g at baseline.
Kidney Disease End Points and Linagliptin13 randomized controlled clinical trials made up of
more than 5,000 individuals with type 2 diabetes. We
found that linagliptin treatment was not associated with
an increase in renal risk. Moreover, linagliptin treat-
ment reduced signiﬁcantly the hazard of kidney disease
end points by 16% when compared with placebo. This
is an intriguing ﬁnding and generates the novel hy-
pothesis that this agentmay have potential to slowCKD
progression in type 2 diabetes, as recently reported
through its effects on the “surrogate” albuminuria.29
The primary aim of our pooled kidney disease
analysis was to rule out an increased renal risk with
linagliptin. It is important to exclude potential dele-
terious effects as a result of drug-drug interactions,
particularly as they pertain to the kidney. For
example, a recent trial targeting dual blockade of the
RAS by combining the novel renin inhibitor aliskiren
with the established classes of either ACE inhibitors
or ARBs in patients with type 2 diabetes supports
such a possibility.11 This trial had to be terminated
prematurely, partially as a result of excess risk for
adverse events (eg, hypotension and hyperkalemia) in
the aliskiren group.30 Of note, in our analysis, lina-
gliptin was not associated with an increased risk of
hypotension or hyperkalemia. Furthermore, this lack
of a deleterious effect of linagliptin was observed in
this cohort, in which 45% of participants were
concomitantly treated with a RAS inhibitor at base-
line. Hence, our analysis indicates that there is no
increased renal or hemodynamic risk with the com-
bined blockade of the RAS and DPP-4 system.
As outlined, the data are consistent with a po-
tential beneﬁcial effect of linagliptin on the onset
and progression of kidney disease in type 2 diabetes.
In line with ﬁndings from this pooled kidney disease
analysis and a previous analysis that has identiﬁed
an albuminuria-lowering effect of linagliptin, which
appears to be at least partially independent of its
glucose-lowering action,29 preclinical studies haveAm J Kidney Dis. 2015;66(3):441-449shown that linagliptin may reduce urinary albumin
excretion, renal ﬁbrosis, oxidative stress, and
inﬂammation in different experimental models.31-35
In the present study, more than 500 individuals
with eGFRs , 60 mL/min/1.73 m2 were included.
Kidney function at baseline did not inﬂuence the
association between reduced renal risk and linagliptin
treatment, indicating a possible renal effect of lina-
gliptin even at advanced stages of CKD. Moreover,
the risk reduction for kidney disease end points with
linagliptin was seen in participants with or without
concomitant treatment with RAS inhibitors at base-
line. Although treatments based on blockade of the
RAS have generally been associated with a reduction
in albuminuria and improved kidney disease outcome
in patients with type 2 diabetes,36,37 there was no
evidence that background ACE-inhibitor and/or ARB
therapy attenuated the renal effects of linagliptin.
Based on positive ﬁndings from the previous
pooled analysis with respect to a potential renal
beneﬁt of linagliptin,29 further research is now
underway to explore glucose-dependent and -inde-
pendent effects of linagliptin in the kidney. Specif-
ically, the MARLINA-T2D trial (Efﬁcacy, Safety
and Modiﬁcation of Albuminuria in Type 2 Dia-
betes Subjects With Renal Disease With Linagliptin;
ClincalTrials.gov study number NCT01792518) is
designed and powered to explore the albuminuria-
lowering potential of linagliptin in patients with
type 2 diabetes and prevalent albuminuria already
treated with ACE inhibitors or ARBs. This 24-week,
randomized, controlled study was initiated in early
2013 and results are expected in 2015.
A major strength of the present study is the large
sample size, which provides greater power to detect
signiﬁcant differences than individual randomized
controlled trials. Nonetheless, we acknowledge that
this pooled kidney disease analysis was of clinical
trials not primarily designed to investigate kidney447
Cooper et aldisease end points. However, safety assessments were
standardized across trials and laboratory assessments
of albuminuria and kidney function were conducted
by a central laboratory. Another limitation is the use
of a primary composite outcome that combines
different kidney disease end points. However, all of
our selected kidney disease end points are likely part
of broader pathologic pathways to kidney failure in
patients with diabetes. Finally, average durations of
the included trials were relatively short, which could
explain the overall low observation rate of signiﬁcant
kidney disease progression and hard kidney disease
outcome events. To address the high unmet medical
need in patients with type 2 diabetes and CKD, the
recently initiated CARMELINA trial (Cardiovascular
and Renal Microvascular Outcome Study With
Linagliptin in Patients With Type 2 Diabetes Mellitus;
ClinicalTrials.gov study number NCT01897532) will
investigate the long-term effect of linagliptin on major
cardiovascular and kidney disease outcomes in adults
with type 2 diabetes at risk of macro- and microvas-
cular events.
In conclusion, it is suggested that emerging data
from clinical development programs should be sys-
tematically used to assess kidney disease end points in
patients with type 2 diabetes treated with new glucose-
lowering agents. Analogous to the current efforts to
better assess cardiovascular safety, renal safety ana-
lyses could provide reliable and valid information on
kidney disease in the early stages of drug develop-
ment. In our analysis, a novel approach for kidney
disease assessments has been developed using the
large clinical trials program of the novel DPP-4 in-
hibitor linagliptin. Linagliptin was not associated with
an increased renal risk but was associated with a
signiﬁcant reduction in clinically relevant kidney
disease end points in patients with type 2 diabetes.
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